{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Zynex, Inc. Stock Plummets to New 52-Week Low of $1.05
Zynex, Inc. has hit a new 52-week low, reflecting significant challenges as it faces an 88.91% stock price decline over the past year. The company has reported nine consecutive quarters of negative results, with substantial losses and a high debt-to-equity ratio, raising concerns about its financial stability.
Zynex, Inc. Stock Plummets to New 52-Week Low at $1.13
Zynex, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting a significant decline in stock performance over the past year. The company has reported negative financial results for nine consecutive quarters, indicating ongoing challenges in its operations and market position.
Zynex, Inc. Stock Plummets to New 52-Week Low of $1.22
Zynex, Inc. has hit a new 52-week low, reflecting a challenging year marked by an 86.8% decline in stock price. The company faces significant financial difficulties, including a pre-tax profit loss and negative operating cash flow, alongside a high debt-to-equity ratio and negative return on equity.
Is Zynex, Inc. technically bullish or bearish?
As of August 1, 2025, Zynex, Inc. is in a bearish trend with weak strength indicators, significantly underperforming the S&P 500 with year-to-date and one-year returns of -80.65% and -81.05%, respectively.
Is Zynex, Inc. overvalued or undervalued?
As of April 29, 2025, Zynex, Inc. is considered risky and overvalued due to negative financial metrics and a year-to-date return of -80.65%, significantly underperforming the S&P 500's 12.22%.
Is Zynex, Inc. overvalued or undervalued?
As of April 29, 2025, Zynex, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 3.30, negative ROE of -35.68%, and significant underperformance with a year-to-date return of -70.16% compared to the S&P 500's 2.44%.
Is Zynex, Inc. technically bullish or bearish?
As of June 9, 2025, Zynex, Inc. shows a mildly bearish trend with mixed signals from key indicators, including a mildly bullish weekly MACD and bearish monthly RSI, suggesting a cautious outlook.
Who are in the management team of Zynex, Inc.?
As of March 2022, Zynex, Inc.'s management team includes Mr. Thomas Sandgaard as Chairman, President, and CEO, along with independent directors Mr. Michael Cress, Mr. Joshua Disbrow, and Mr. Barry Michaels.
What does Zynex, Inc. do?
Zynex, Inc. manufactures medical devices for treating pain and rehabilitating muscles, with a market cap of $74.31 million and quarterly net sales of $27 million but a net loss of $10 million as of March 2025. Key metrics include a debt-to-equity ratio of 1.89 and a return on equity of -35.68%.
How big is Zynex, Inc.?
As of Jun 18, Zynex, Inc. has a market capitalization of 74.31 million and reported net sales of 172.40 million with a net profit of -7.41 million over the latest four quarters. Shareholder's funds are 35.71 million, and total assets amount to 126.11 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
